US Stock Futures Mixed; All Eyes On Apple, Microsoft Earnings
US stock futures traded mixed in early pre-market trade. Apple Inc. (NASDAQ: AAPL), Microsoft Corporation (NASDAQ: MSFT) and Yahoo! Inc. (NASDAQ: YHOO) will release latest quarter earnings after the closing bell today. Futures for the Dow Jones Industrial Average dropped 11.50 points to 17,991.5, while the Standard & Poor's 500 index futures rose 0.45 points to 2,122.45. Futures for the Nasdaq 100 index gained 6.55 points to 4,677.80.
A Peek Into Global Markets
European markets were mixed today, with the Spanish Ibex Index falling 0.05 percent, STOXX Europe 600 Index declining 0.09 percent and German DAX 30 index climbing 0.09 percent. French CAC 40 Index jumped 0.16 percent and London's FTSE 100 Index rose 0.13 percent.
In Asian markets, Japan's Nikkei Stock Average climbed 0.93 percent, Hong Kong's Hang Seng Index rose 0.52 percent, China's Shanghai Composite Index rose 0.64 percent and India's BSE Sensex slipped 0.84 percent.
Analysts at UBS downgraded Tesla Motors Inc (NASDAQ: TSLA) from Neutral to Sell. The target price for Tesla has been lowered from $220 to $210.
Tesla shares closed at $282.26 yesterday.
- Medidata Solutions Inc (NASDAQ: MDSO) and Validic today announced a collaboration to propel connectivity and innovation in clinical research by expanding access to patient-generated data from a broad range of consumer and medical grade mobile health (mHealth) devices and apps. To read the full news, click here.
- Infosys Ltd ADR (NYSE: INFY) today announced a definitive agreement for an investment in ANSR Consulting to acquire a minority stake. To read the full news, click here.
- Sunedison Inc (NYSE: SUNE) today announced that it has acquired Mark Group, based in Leicester, United Kingdom, the country's leading full service energy solutions provider and a SunEdison solar sales and installation partner. To read the full news, click here.
- Amgen, Inc.(NASDAQ: AMGN) today announced that the European Commission has granted marketing authorization for Repatha™, the first proprotein convertase subtilisin/kexin type 9 inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. To read the full news, click here.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.